Amneal Intermediate Inc
NASDAQ:AMRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Amneal Intermediate Inc
NASDAQ:AMRX
|
US |
|
Guangdong Huicheng Vacuum Technology Co Ltd
SZSE:301392
|
CN |
|
Betsson AB
STO:BETS B
|
SE |
|
B
|
Beijing SunwayWorld Science & Technology Co Ltd
SZSE:301159
|
CN |
|
Q
|
Qibu Corp Ltd
SSE:603557
|
CN |
|
S
|
Sichuan Baicha Baidao Industrial Co Ltd
HKEX:2555
|
CN |
|
L E Lundbergforetagen AB (publ)
STO:LUND B
|
SE |
Revenue Breakdown
Breakdown by Geography
Amneal Intermediate Inc
Breakdown by Segments
Amneal Intermediate Inc
|
Total Revenue:
3B
USD
|
|
Subtotal Dosage Forms:
1.7B
USD
|
|
Oral Solid:
689.4m
USD
|
|
Subtotal Therapeutic Classes:
439.2m
USD
|
|
Distribution:
434m
USD
|
|
Central Nervous System:
280.2m
USD
|
|
Auto-Injector:
209.5m
USD
|
|
Other Dosage Forms:
202.2m
USD
|
|
Transdermal:
180.9m
USD
|
|
Injectable:
165.4m
USD
|
|
Government:
160m
USD
|
|
Hormonal / Allergy:
130.4m
USD
|
|
Biosimilar:
125.4m
USD
|
|
Oral Liquid:
103.4m
USD
|
|
Institutional:
42.8m
USD
|
|
Other Therapeutic Classes:
28.6m
USD
|
|
Other:
26.3m
USD
|
|
International:
9m
USD
|
|
License Agreement:
6.5m
USD
|